Normal Tissue Perfusion Changes During Everolimus Treatment: Preliminary Results from a Functional Vascular Study Abstract #1007

Introduction: Everolimus (E) acts on cancer progression, even inhibiting tumor angiogenesis. Both tumor vasculature and a normal one could undergo everolimus effect.
Aim(s): To analyze short-term changes in vascular function caused by E in patients with pNETs.
Materials and methods: In four patients with advanced E-treated pNETs, at baseline (B), after one month (T1) and 2 months (T2), we evaluated: central blood pressures (CBP), Augmentation Index (AIx) and Pulse Wave Velocity (PWV) using Sphygmocor as markers of arterial stiffness and arteriolar resistance, microcircular perfusion flow (PF) and vasodilatation response to ischemia (VDRI) using Laser-Doppler Flowmetry as a marker of endothelial function.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sara Cingarlini

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1381 [18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour
Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1210 Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study.
Introduction: P-CT can evaluate inner perfusional features of primary and metastatic PanNETs; preliminary evidences suggest its potential role in predicting early response to anti-angiogenic therapies. Perfusional modifications induced by E in LM are not completely understood.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1705 Prostate-Specific Membrane Antigen (PSMA) Uptake in a Pancreatic Neuroendocrine Tumor (pNET) Bearing Patient
Introduction: Prostate-specific membrane antigen (PSMA) is a transmembrane protein overexpressed on both prostate epithelial malignant cells and endothelial cells of tumor-associated neovasculature of many solid cancers. PSMA has been investigated already as a target in staging and detection of prostate cancer
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Elisabetta Grego
#999 Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study
Introduction: Criteria other than RECIST are not validated for evaluation of response during treatment in pancreatic neuroendocrine tumors (pNETs). Preliminary evidence favors antiangiogenic properties of E.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sara Cingarlini
Keywords: everolimus, pNET, P-CT
#1023 Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience
Introduction: STZ is the only FDA-approved antiblastic drug for well-/moderately-differentiated NETs. To date, no clear therapeutic sequence is defined for medical treatment of advanced pNETs.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Sara Cingarlini